Ignite Creation Date:
2025-12-24 @ 5:19 PM
Ignite Modification Date:
2026-01-24 @ 5:39 PM
Study NCT ID:
NCT02289950
Status:
COMPLETED
Last Update Posted:
2021-09-02
First Post:
2014-11-10
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer
Sponsor:
Eisai Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-03-19
Start Date Type:
ACTUAL
Primary Completion Date:
2019-05-31
Primary Completion Date Type:
ACTUAL
Completion Date:
2020-08-13
Completion Date Type:
ACTUAL
First Submit Date:
2014-11-10
First Submit QC Date:
None
Study First Post Date:
2014-11-13
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2021-08-09
Results First Submit QC Date:
None
Results First Post Date:
2021-09-02
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2020-05-29
Disp First Post Date Type:
ACTUAL
Last Update Submit Date:
2021-08-09
Last Update Post Date:
2021-09-02
Last Update Post Date Type:
ACTUAL